Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
IFN-κ is critical for normal wound repair and is decreased in diabetic wounds
Sonya J. Wolf, … , J. Michelle Kahlenberg, Katherine A. Gallagher
Sonya J. Wolf, … , J. Michelle Kahlenberg, Katherine A. Gallagher
Published March 31, 2022
Citation Information: JCI Insight. 2022;7(9):e152765. https://doi.org/10.1172/jci.insight.152765.
View: Text | PDF
Research Article Inflammation

IFN-κ is critical for normal wound repair and is decreased in diabetic wounds

  • Text
  • PDF
Abstract

Wound repair following acute injury requires a coordinated inflammatory response. Type I IFN signaling is important for regulating the inflammatory response after skin injury. IFN-κ, a type I IFN, has recently been found to drive skin inflammation in lupus and psoriasis; however, the role of IFN-κ in the context of normal or dysregulated wound healing is unclear. Here, we show that Ifnk expression is upregulated in keratinocytes early after injury and is essential for normal tissue repair. Under diabetic conditions, IFN-κ was decreased in wound keratinocytes, and early inflammation was impaired. Furthermore, we found that the histone methyltransferase mixed-lineage leukemia 1 (MLL1) is upregulated early following injury and regulates Ifnk expression in diabetic wound keratinocytes via an H3K4me3-mediated mechanism. Using a series of in vivo studies with a geneticall y engineered mouse model (Mll1fl/fl K14cre–) and human wound tissues from patients with T2D, we demonstrate that MLL1 controls wound keratinocyte–mediated Ifnk expression and that Mll1 expression is decreased in T2D keratinocytes. Importantly, we found the administration of IFN-κ early following injury improves diabetic tissue repair through increasing early inflammation, collagen deposition, and reepithelialization. These findings have significant implications for understanding the complex role type I IFNs play in keratinocytes in normal and diabetic wound healing. Additionally, they suggest that IFN may be a viable therapeutic target to improve diabetic wound repair.

Authors

Sonya J. Wolf, Christopher O. Audu, Amrita Joshi, Aaron denDekker, William J. Melvin, Frank M. Davis, Xianying Xing, Rachael Wasikowski, Lam C. Tsoi, Steven L. Kunkel, Johann E. Gudjonsson, Mary X. O’Riordan, J. Michelle Kahlenberg, Katherine A. Gallagher

×

Figure 3

Impaired IFN-κ production in human diabetic wounds.

Options: View larger image (or click on image) Download as PowerPoint
Impaired IFN-κ production in human diabetic wounds.
(A) Whole wounds wer...
(A) Whole wounds were isolated from 2 diabetic models (DIO and db/db) and their respective controls; n = 3–6 per group. Ifnk gene expression was measured via qPCR. (B) Human wounds were collected from T2D patients with chronic diabetic foot ulcers and non-T2D; n = 3–8 per group. IFNk gene expression was measured via qPCR. (C) Representative staining for IFN-κ performed on wounds from T2D and non-T2D patient skin. Magnification, ×10. (D) Keratinocytes were isolated at baseline from the tail of db/db mice and their controls; n = 4 per group, repeated in triplicate. Ifnk expression was measured via qPCR. Data were analyzed for variances, and 2-tailed Student’s t test or Mann-Whitney U test was performed. *P < 0.05 and **P < 0.01. Data are presented as mean ± SEM.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts